Crenigacestat

Drug Profile

Crenigacestat

Alternative Names: LY-3039478

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Benzazepines; Small molecules
  • Mechanism of Action Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Lymphoma
  • Phase I Cancer; Solid tumours
  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Hepatocellular carcinoma in USA (PO) before April 2017
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Hepatocellular carcinoma presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 11 Jan 2017 Eli Lilly collaborates with NCI Formulary to co-develop LY 3039478 in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top